Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
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
ZsSVh8TJSPKT6pJt
Listen
